Cell Cycle · 2012 · 52 citations · 45 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMedical OncologyChemotherapy Toxicity ManagementCytotoxic ChemotherapyP53-mediated Cell Cycle ArrestP53-mediated Cell Cycle RegulationP53-mediated Cell-cycle Arrest
Pharmacological activation of wild-type p53 has been found to protect normal cells in culture from cytotoxicity and nuclear aberrations caused by conventional cancer therapeutics. Hence, small-molecule p53 activators could have clinical benefits as chemoprotectants for cancer patients bearing p53-mutant tumors. We have evaluated 16 p53-based cyclotherapy regimes combining p53 activators tenovin-6, leptomycin B, nutlin-3 and low dose actinomycin D, with clinically utilized chemotherapeutic agents (S- and M-phase poisons), vinblastine, vinorelbine, cytosine arabinoside and gemcitabine. All the p53 activators induce reversible cell-cycle arrest in primary human fibroblasts and protect them from both S- and M-phase poisons. Furthermore, studies with p53-mutant cancer cell lines show that nutlin-3 and low dose actinomycin D do not affect the sensitivity of these cells to any of the chemotherapeutics tested. Thus, these two small molecules could be suitable choices for cyclotherapy regimes involving S- or M-phase poisons. In contrast, pre-incubation of p53-mutant cells with tenovin-6 or leptomycin B reduces the efficacy of vinca alkaloids, suggesting that these p53 activators could be effective as chemoprotectants if combined with S- but not M-phase poisons. Discrepancies were observed between the levels of protection detected immediately after treatment and following recovery in fresh medium. This highlights the need to assess both short- and long-term effects when evaluating compounds as potential chemoprotectants for cancer therapy.
45
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Lyubomir T. Vassilev, Binh Thanh Vu, Bradford Graves et al. · Science · 2004 · 4.7K citations
Medicine, Oncology, Pharmacology +15
Selective killing of cancer cells by a small molecule targeting the stress response to ROS
Lakshmi Raj, Takao Ide, Aditi U. Gurkar et al. · Nature · 2011 · 1K citations
Medicine, Cancer Biology, Oncology +15
Impaired DNA Damage Response, Genome Instability, and Tumorigenesis in SIRT1 Mutant Mice
Rui-Hong Wang, Kundan Sengupta, Cuiling Li et al. · Cancer Cell · 2008 · 776 citations · Full text
Regulation of HDM2 activity by the ribosomal protein L11
Marion Lohrum, Robert L. Ludwig, Michael H.G. Kubbutat et al. · Cancer Cell · 2003 · 616 citations · Full text